Mavacamten HCM denied due to quantity / dose limits by Aetna?

Aetna's specific coverage criteria for mavacamten hcm are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Places Quantity Limits on Mavacamten — and Why You Can Appeal

Mavacamten is dispensed under a Risk Evaluation and Mitigation Strategy (REMS) program due to its cardiovascular monitoring requirements, and it is prescribed at doses that are individually titrated based on echocardiographic assessment. Aetna's quantity limits for mavacamten are designed to align dispensing with the titration schedule and monitoring intervals required by the FDA-approved prescribing label. A quantity-limit denial typically arises when the amount requested — in terms of tablet count, supply days, or strength — does not match the insurer's automated coverage parameters.

## Why Quantity-Limit Denials Are Appealable

Because mavacamten titration is individualized and guided by ongoing echocardiographic monitoring, the quantity required at any given fill can legitimately differ from a standard supply interval. If the prescriber has documented the clinical basis for the quantity requested — including where the patient is in the titration sequence and what monitoring has been completed — the appeal is typically straightforward. The key is demonstrating that the requested quantity is consistent with the FDA-approved prescribing label and the patient's current titration status.

## Federal Appeal Framework

• Internal appeal: File within the timeframe stated in the denial letter. Attach a prescriber letter explaining the titration status and how the requested quantity aligns with the FDA label.
• External review (ACA §2719): Available after exhausting internal appeals, generally within four months of the final denial for most non-grandfathered plan members.
• ERISA §503: Employer-plan members have full-and-fair review rights, including the right to all clinical criteria relied on in the denial.
• Expedited review: Request if a gap in therapy due to the quantity restriction poses serious clinical risk, particularly given the cardiovascular monitoring requirements of the REMS program.

## Documentation to Gather

• Current titration status: A prescriber note or letter documenting where in the titration sequence the patient currently is, including what echocardiographic assessments have been completed and what monitoring is upcoming.
• FDA label reference: Confirmation from the prescriber that the requested quantity is consistent with the titration and monitoring schedule in the FDA-approved prescribing information.
• REMS enrollment confirmation: Documentation of enrollment in the mavacamten REMS program, confirming compliance with monitoring requirements.
• Diagnosis and treatment history: Specialist records confirming the oHCM diagnosis and the ongoing clinical rationale for mavacamten therapy.

## Criteria-Mapping Structure

Obtain Aetna's quantity-limit policy for mavacamten. Map each requirement:

| Policy Requirement | Supporting Documentation | |---|---| | Quantity consistent with FDA-approved dosing schedule | [Prescriber letter referencing label titration guidance] | | Clinical justification for quantity requested | [Titration status note, echocardiographic monitoring record] | | REMS program enrollment | [REMS enrollment confirmation] | | Ongoing monitoring compliance | [Scheduled and completed echo assessments] |

A concise prescriber letter explaining the titration context is almost always the decisive document in these appeals.